El CSIC participa en la mayor expedición científica al Ártico de la historia

SIMPATICO es el acrónimo de "Spanish contribution to Mosaic: Primary aerosol transport in the Arctic Atmosphere". Está dirigido por Manuel Dall'Osto, científico del Instituto de Ciencias del Mar del CSIC (ICM-CSIC) y es uno de los proyectos integrados en la Expedición MOSAIC, la mayor expedición científica al Ártico de la historia. El objetivo de la misión es estudiar el Ártico como epicentro del calentamiento global para obtener datos que permitan comprender mejor el cambio climático global. El proyecto reúne 600 investigadores de 19 países que trabajarán de forma rotativa, e incluye tres equipos de investigación españoles, todos del CSIC, procedentes del Instituto de Ciencias del Mar, de Barcelona, y del Instituto de Ciencias del Espacio/Instituto de Estudios Espaciales de Cataluña y financiados por la Agencia Estatal de InvestigaciónPeer reviewe

Synthesis, in vitro profiling, and in vivo efficacy studies of a new family of multitarget anti-alzheimer compounds

Simultaneous modulation of several targets or pathological events with a key pathogenic role is a promising strategy to tackle thus far difficult-to-cure or incurable multifactorial diseases, such as Alzheimer’s disease (AD). In this scenario, multitarget compounds, i.e., single molecules that hit several targets, are superior to other multitarget strategies that are based on the use of more than one drug (drug cocktails, fixed-dose combinations), in terms of simpler drug development and better patient compliance, efficiency, and safety.Peer reviewe

Acción piloto para la restauración de gorgonias en el Parc Natural del Montgrí, Illes Medes i Baix Ter

Acción piloto para la restauración de gorgonias en el Parc Natural del Montgrí, Illes Medes i Baix TerPeer reviewe

10. European workshop on white dwarfs

AbstractsCentro de Informacion y Documentacion Cientifica (CINDOC). C/Joaquin Costa, 22. 28002 Madrid. SPAIN / CINDOC - Centro de Informaciòn y Documentaciòn CientìficaSIGLEESSpai

Synthesis, in vitro profiling, and in vivo efficacy studies of a new family of multitarget antiAlzheimer compounds

Simultaneous modulation of several targets or athological events with a key pathogenic role is a promising strategy to tackle thus far difficult-to-cure or incurable multifactorial diseases, such as Alzheimer's disease (AD). In this scenario, multitarget compounds, i.e., single molecules that hit several targets, are superior to other multitarget strategies that are based on the use of more than one drug (drug cocktails, fixed-dose combinations), in terms of simpler drug development and better patient compliance, efficiency, and safety

Search for the Higgs boson produced with Z→ℓ+ℓ−Z \to \ell^+\ell^- in ppˉp\bar{p} collisions at s=\sqrt{s}= 1.96 TeV

The authors present a search for the Higgs boson in the process q{bar q} {yields} ZN {yields} {ell}{sup +}{ell}{sup -} b{bar b}. The analysis uses an integrated luminosity of 1 fb{sup -1} of p{bar p} collisions produced at {radical}s = 1.96 TeV and accumulated by the upgraded Collider Detector at Fermilab (CDF II). They employ artificial neural networks both to correct jets mismeasured in the calorimeter, and to distinguish the signal kinematic distributions from those of the background. They see no evidence for Higgs boson production, and set 95% CL upper limits on {sigma}{sub ZH} {center_dot} {Beta}(H {yields} b{bar b}), ranging from 1.5 pb to 1.2 pb for a Higgs mass (m{sub H}) of 110 to 150 GeV/c{sup 2}